3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
30
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Solid Cancer
1
Interventions
Temozolomide
17
Radiotherapy
8
Surgical Procedures, Operative
6
Flucytosine
6
vocimagene amiretrorepvec
5
IL13-PE38
5
Lomustine
4
Valacyclovir
3
Radiation
3
Corticotropin-Releasing Hormone
3
Chlorotoxin
3
Carmustine
3
Bevacizumab
3
vorasidenib
2
trametinib
2
tovorafenib
2
regorafenib
2
pembrolizumab
2
paclitaxel-Angiopep-2 conjugate
2
dabrafenib
2
Trabedersen
2
OKN 007
2
Nivolumab
2
Everolimus
2
Eflornithine
2
Drug Delivery Systems
2
Carboplatin
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Astrocytoma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled